First-in-Class Oral ENV-294 Evaluated in Atopic Dermatitis, With Leon Kircik, MD

ENV-294, an investigational first-in-class oral Rac2 modulator, produced substantial reductions in Eczema Area and Severity Index (EASI) scores in a small phase 1b open-label study in moderate to severe atopic dermatitis, with improvement continuing after treatment ended.¹

Leon Kircik, MD, an investigator on the study who enrolled its first participant, discussed the results with HCPLive ahead of his presentation at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.¹

Kircik noted dermatologists have several effective biologics for atopic dermatitis but few oral small molecule options beyond Janus kinase (JAK) inhibitors. He described ENV-294, developed by Enveda Biosciences, as an entirely new molecule and an important potential addition to the oral treatment landscape.

What Did the Phase 1b Study of ENV-294 Show?

Kircik presented the findings in an abstract describing deep, durable efficacy and a favorable safety profile for ENV-294 in moderate to severe atopic dermatitis.¹

The study enrolled 9 participants, who were given ENV-294 as monotherapy for 28 days, followed by an off-treatment period through Day 42. No concomitant therapies were permitted other than moisturizers. At Day 28, EASI scores fell by 68%. By day 42, 2 weeks after the final dose, the reduction had deepened to 85%. Kircik highlighted this continued improvement after discontinuation as a key observation from the study.

Onset of action was also rapid, according to Kircik, with a sharp decline in the EASI curve evident by the 8-day mark.

How Safe Was ENV-294 in Atopic Dermatitis?

Kircik emphasized safety as the most important consideration for any novel agent. The only adverse event reported was a single mild headache, and there were no treatment-related adverse events.

He acknowledged the brief 28-day treatment period limits what the safety data can show, though no concerning signals emerged.

What Comes Next for ENV-294?

Kircik urged cautious optimism, citing the open-label design and small sample size. A double-blind, placebo-controlled phase 2 trial is underway and still enrolling, and he said results are likely some time away. ENV-294 has not been approved by any regulatory authority and does not yet have a generic name.

Editor's Note: This summary has been edited for grammar and clarity using artificial intelligence tools.

References

1. Kircik L, et al. ENV-294, a first-in-class oral Rac2 modulator, demonstrates deep, durable efficacy with a favorable safety profile in moderate-to-severe atopic dermatitis: results from a phase 1b open-label study. Presented at: 2026 European Academy of Dermatology and Venereology Congress; September 30-October 3, 2026; Vienna, Austria.